⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 28, 2024Anticancer Research

Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing

Hyun-Woo Lee YOON AH CHO Deok Geun Kim JAE YOUNG SON Eun Yoon Cho

View Full Paper

Ask AI

Bookmark

Share

Abstract

TP53 mutation in breast cancer (BC) is associated with chemoresistance, endocrine therapy resistance, and late recurrence, resulting in poor prognosis. Nuclear accumulation of p53 in immunohistochemistry (IHC) is a surrogate marker of TP53 mutation. This study analyzed the frequency, type, and distribution of TP53 mutations in BCs and assessed the efficacy of p53 IHC as a surrogate marker of TP53 mutation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2024) studied this question.

synapsesocial.com/papers/68e5a94ab6db6435875430a2 https://doi.org/10.21873/anticanres.17227

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1P53 immunohistochemistry is an ideal surrogate marker for TP53 mutation and a predictor of early metastasis in breast cancer: Real-world analysis2024 · 1 citations
2p53 protein expression patterns associated with TP53 mutations in breast carcinoma2024 · 19 citations
3Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations2024 · 8 citations
4Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple-negative breast cancer2024 · 1 citations
5A Retrospective Study of the Correlation Between Next-Generation Sequencing and Immunohistochemical Detection of TP53 in Colorectal CancerRetrospective Study · 2026 · 2 citations